KALA BIO, Inc. (KALA) stock
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.43−0.40 (-10.44%)
Close on Nov 17, 2026Market cap $66.34MP/E –Yield –
Kala Bio r&d expenses
Research and development expenses are spending on new products and technology.
Kala Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.61M, down 70.9% year over year. For fiscal 2025 it was $18.78M, down 15.0% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $29.29M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.78M | -15.0% |
| FY2024 | Dec 31, 2024 | $22.09M | +18.9% |
| FY2023 | Dec 31, 2023 | $18.59M | +5.3% |
| FY2022 | Dec 31, 2022 | $17.65M | +53.3% |
| FY2021 | Dec 31, 2021 | $11.52M | -37.3% |
| FY2020 | Dec 31, 2020 | $18.35M | -32.7% |
| FY2019 | Dec 31, 2019 | $27.28M | -6.9% |
| FY2018 | Dec 31, 2018 | $29.29M | +1.0% |
| FY2017 | Dec 31, 2017 | $29.01M | +15.9% |
| FY2016 | Dec 31, 2016 | $25.03M | +119.9% |
| FY2015 | Dec 31, 2015 | $11.38M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $59.00K | -99.1% |
| Q1 FY2026 | Mar 31, 2026 | $61.00K | -99.0% |
| Q4 FY2025 | Dec 31, 2025 | $366.00K | -93.0% |
| Q3 FY2025 | Sep 30, 2025 | $6.13M | +18.6% |
| Q2 FY2025 | Jun 30, 2025 | $6.23M | +17.2% |
| Q1 FY2025 | Mar 31, 2025 | $6.06M | -4.7% |
| Q4 FY2024 | Dec 31, 2024 | $5.26M | +11.4% |
| Q3 FY2024 | Sep 30, 2024 | $5.17M | -6.9% |
| Q2 FY2024 | Jun 30, 2024 | $5.32M | +24.3% |
| Q1 FY2024 | Mar 31, 2024 | $6.35M | +57.4% |
| Q4 FY2023 | Dec 31, 2023 | $4.72M | +42.0% |
| Q3 FY2023 | Sep 30, 2023 | $5.55M | +3.0% |
| Q2 FY2023 | Jun 30, 2023 | $4.28M | -4.4% |
| Q1 FY2023 | Mar 31, 2023 | $4.04M | -9.6% |
| Q4 FY2022 | Dec 31, 2022 | $3.32M | +37.7% |
| Q3 FY2022 | Sep 30, 2022 | $5.39M | +87.1% |
| Q2 FY2022 | Jun 30, 2022 | $4.47M | +44.6% |
| Q1 FY2022 | Mar 31, 2022 | $4.47M | +42.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.41M | -28.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.88M | -16.9% |
| Q2 FY2021 | Jun 30, 2021 | $3.09M | -48.9% |
| Q1 FY2021 | Mar 31, 2021 | $3.13M | -42.5% |
| Q4 FY2020 | Dec 31, 2020 | $3.40M | -44.7% |
| Q3 FY2020 | Sep 30, 2020 | $3.47M | -50.9% |
| Q2 FY2020 | Jun 30, 2020 | $6.05M | -14.8% |
| Q1 FY2020 | Mar 31, 2020 | $5.43M | -21.9% |
| Q4 FY2019 | Dec 31, 2019 | $6.14M | -33.6% |
| Q3 FY2019 | Sep 30, 2019 | $7.07M | +0.6% |
| Q2 FY2019 | Jun 30, 2019 | $7.11M | -3.5% |
| Q1 FY2019 | Mar 31, 2019 | $6.96M | +23.0% |
| Q4 FY2018 | Dec 31, 2018 | $9.24M | +57.1% |
| Q3 FY2018 | Sep 30, 2018 | $7.03M | +0.1% |
| Q2 FY2018 | Jun 30, 2018 | $7.37M | -8.7% |
| Q1 FY2018 | Mar 31, 2018 | $5.66M | -29.6% |
| Q4 FY2017 | Dec 31, 2017 | $5.88M | -14.9% |
| Q3 FY2017 | Sep 30, 2017 | $7.02M | -15.0% |
| Q2 FY2017 | Jun 30, 2017 | $8.07M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.04M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.91M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.26M | – |
See a number that looks wrong?